We are analyzing https://link.springer.com/article/10.1186/bcr2835.

Title:
Therapeutic targets for bone metastases in breast cancer | Breast Cancer Research
Description:
Breast cancer is prone to metastasize to bone. Once metastatic cells are in the bone marrow, they do not, on their own, destroy bone. Instead, they alter the functions of bone-resorbing (osteoclasts) and bone-forming cells (osteoblasts), resulting in skeletal complications that cause pathological fractures and pain. In this review, we describe promising molecular bone-targeted therapies that have arisen from recent advances in our understanding of the pathogenesis of breast cancer bone metastases. These therapies target osteoclasts (receptor activator of nuclear factor kB ligand, integrin αvβ3, c-Src, cathepsin K), osteoblasts (dickkopf-1, activin A, endothelin A) and the bone marrow microenvironment (transforming growth factor β, bone morphogenetic proteins, chemokine CXCL-12 and its receptor CXCR4). The clinical exploitation of these bone-targeted agents will provide oncologists with novel therapeutic strategies for the treatment of skeletal lesions in breast cancer.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Science
Health & Fitness
Education

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,642,828 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We don’t know how the website earns money.

Not all websites focus on profit; some are designed to educate, connect people, or share useful tools. People create websites for numerous reasons. And this could be one such example. Link.springer.com might have a hidden revenue stream, but it's not something we can detect.

Keywords {🔍}

bone, cancer, breast, pubmed, article, google, scholar, cells, cas, metastasis, metastases, tumor, patients, growth, clinical, resorption, therapeutic, cathepsin, cell, central, formation, tgfβ, trials, skeletal, inhibitors, metastatic, inhibitor, osteoclasts, receptor, osteoclast, signaling, rankl, csrc, cxcr, factors, activity, dkk, targets, factor, integrin, treatment, stimulate, role, inhibition, phase, receptors, clézardin, target, αvβ, activin,

Topics {✒️}

/media/press-releases/article/0022011astrazeneca-halts-phase-iii-trial specific g-protein-coupled receptors proto-oncogene tyrosine-protein kinase tumor-derived matrix metallo-proteinase transmembrane serine/threonine kinases macrophage-colony stimulating factor farnesyl pyrophosphate synthase parathyroid hormone-related protein parathyroid hormone-related peptide nuclear factor-kb ligand osteoclast-mediated bone resorption tgf-β-related therapy γ-secretase inhibitors bone-targeted therapies src-dependent survival signals tgf-β signaling offers antagonizes tgf-β signaling cancer-induced bone diseases jagged1/notch signaling pathways wnt-signaling antagonist dkk1 //breast-cancer-research transforming growth factor-β bone-derived growth factors dkk1-neutralizing antibody bhq880 tyrosine kinases c-src c-src frequently occurs full size image rgd peptide derived bone-targeted agents anti-dkk1 mab bone-targeted strategies inhibits bone resorption subsequent skeletal-related events nuclear factor kb targeted therapies decreases osteoclast activity cxcr4/sdf-1 chemokine axis successfully block osteolysis inhibits bone metastasis rank-expressing osteoclast major cysteine protease inhibit bone resorption privacy choices/manage cookies improve existing therapies metastatic breast cancer breast cancer metastases phase ii trial bone resorption markers stimulate osteoclast differentiation breast cancer cells

Questions {❓}

Hirbe AC, Morgan EA, Weilbaecher KN: The CXCR4/SDF-1 chemokine axis: a potential therapeutic target for bone metastases?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Therapeutic targets for bone metastases in breast cancer
         description:Breast cancer is prone to metastasize to bone. Once metastatic cells are in the bone marrow, they do not, on their own, destroy bone. Instead, they alter the functions of bone-resorbing (osteoclasts) and bone-forming cells (osteoblasts), resulting in skeletal complications that cause pathological fractures and pain. In this review, we describe promising molecular bone-targeted therapies that have arisen from recent advances in our understanding of the pathogenesis of breast cancer bone metastases. These therapies target osteoclasts (receptor activator of nuclear factor kB ligand, integrin αvβ3, c-Src, cathepsin K), osteoblasts (dickkopf-1, activin A, endothelin A) and the bone marrow microenvironment (transforming growth factor β, bone morphogenetic proteins, chemokine CXCL-12 and its receptor CXCR4). The clinical exploitation of these bone-targeted agents will provide oncologists with novel therapeutic strategies for the treatment of skeletal lesions in breast cancer.
         datePublished:2011-04-06T00:00:00Z
         dateModified:2011-04-06T00:00:00Z
         pageStart:1
         pageEnd:9
         sameAs:https://doi.org/10.1186/bcr2835
         keywords:
            Breast Cancer
            Breast Cancer Cell
            Bone Resorption
            Bone Metastasis
            Denosumab
            Cancer Research
            Oncology
            Surgical Oncology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr2835/MediaObjects/13058_2011_2670_Fig1_HTML.jpg
         isPartOf:
            name:Breast Cancer Research
            issn:
               1465-542X
            volumeNumber:13
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Philippe Clézardin
               affiliation:
                     name:INSERM, UMR1033
                     address:
                        name:INSERM, UMR1033, Lyon, France
                        type:PostalAddress
                     type:Organization
                     name:University of Lyon
                     address:
                        name:University of Lyon, Lyon, France
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Therapeutic targets for bone metastases in breast cancer
      description:Breast cancer is prone to metastasize to bone. Once metastatic cells are in the bone marrow, they do not, on their own, destroy bone. Instead, they alter the functions of bone-resorbing (osteoclasts) and bone-forming cells (osteoblasts), resulting in skeletal complications that cause pathological fractures and pain. In this review, we describe promising molecular bone-targeted therapies that have arisen from recent advances in our understanding of the pathogenesis of breast cancer bone metastases. These therapies target osteoclasts (receptor activator of nuclear factor kB ligand, integrin αvβ3, c-Src, cathepsin K), osteoblasts (dickkopf-1, activin A, endothelin A) and the bone marrow microenvironment (transforming growth factor β, bone morphogenetic proteins, chemokine CXCL-12 and its receptor CXCR4). The clinical exploitation of these bone-targeted agents will provide oncologists with novel therapeutic strategies for the treatment of skeletal lesions in breast cancer.
      datePublished:2011-04-06T00:00:00Z
      dateModified:2011-04-06T00:00:00Z
      pageStart:1
      pageEnd:9
      sameAs:https://doi.org/10.1186/bcr2835
      keywords:
         Breast Cancer
         Breast Cancer Cell
         Bone Resorption
         Bone Metastasis
         Denosumab
         Cancer Research
         Oncology
         Surgical Oncology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr2835/MediaObjects/13058_2011_2670_Fig1_HTML.jpg
      isPartOf:
         name:Breast Cancer Research
         issn:
            1465-542X
         volumeNumber:13
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Philippe Clézardin
            affiliation:
                  name:INSERM, UMR1033
                  address:
                     name:INSERM, UMR1033, Lyon, France
                     type:PostalAddress
                  type:Organization
                  name:University of Lyon
                  address:
                     name:University of Lyon, Lyon, France
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Breast Cancer Research
      issn:
         1465-542X
      volumeNumber:13
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:INSERM, UMR1033
      address:
         name:INSERM, UMR1033, Lyon, France
         type:PostalAddress
      name:University of Lyon
      address:
         name:University of Lyon, Lyon, France
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Philippe Clézardin
      affiliation:
            name:INSERM, UMR1033
            address:
               name:INSERM, UMR1033, Lyon, France
               type:PostalAddress
            type:Organization
            name:University of Lyon
            address:
               name:University of Lyon, Lyon, France
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:INSERM, UMR1033, Lyon, France
      name:University of Lyon, Lyon, France

External Links {🔗}(198)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.87s.

LINK . SPRINGER . COM {}